- Home
- CB vs BSX Comparison
CB vs BSX Comparison
Compare CB & BSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CB | BSX |
|---|---|---|
| Founded | 1985 | 1979 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 129.7B | 137.8B |
| IPO Year | 1995 | 2010 |
Fundamental Metrics
Financial Performance| Metric | CB | BSX |
|---|---|---|
| Price | $329.58 | $68.54 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 19 | 20 |
| Target Price | ★ $332.00 | $108.75 |
| AVG Volume (30 Days) | 1.5M | ★ 11.6M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.20% | N/A |
| EPS Growth | 13.13 | ★ 55.20 |
| EPS | ★ 25.68 | 1.94 |
| Revenue | ★ $59,402,000,000.00 | $9,076,000,000.00 |
| Revenue This Year | N/A | $12.04 |
| Revenue Next Year | $5.31 | $10.48 |
| P/E Ratio | ★ $12.58 | $35.87 |
| Revenue Growth | 6.54 | ★ 12.49 |
| 52 Week Low | $264.10 | $68.25 |
| 52 Week High | $345.67 | $109.50 |
Technical Indicators
Market Signals| Indicator | CB | BSX |
|---|---|---|
| Relative Strength Index (RSI) | 53.51 | 28.12 |
| Support Level | $322.43 | N/A |
| Resistance Level | $335.60 | $76.77 |
| Average True Range (ATR) | 5.68 | 1.86 |
| MACD | -2.06 | 0.04 |
| Stochastic Oscillator | 40.10 | 11.95 |
Price Performance
Historical ComparisonAbout CB Chubb Limited
ACE acquired Chubb in the first quarter of 2016 and assumed the Chubb name. The combination made the new Chubb one of the largest domestic property and casualty insurers, with operations in 54 countries spanning commercial and personal P&C insurance, reinsurance, and life insurance.
About BSX Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.